Communiqués Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:36:07 08/10/2026			Varia. 5j.	Varia. 1 janv.
12,08 ^USD	+3,20%		-0,58%	+34,04%

06/10	Intellia Therapeutics, Inc. : Barclays révise son opinion et passe vendeur	ZM
14/09	Transcript : Intellia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 04:05 PM

Communiqués

02/10	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
08/09	Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)	AQ
04/09	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/09	Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million	AQ
04/09	Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference	AQ
07/08	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/08	Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	AQ
30/07	Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates	AQ
06/07	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/06	Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema	AQ
05/06	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/06	Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026	AQ
11/05	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Intellia Therapeutics to Participate in Upcoming Investor Conferences	AQ
04/05	Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema	AQ
01/05	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
29/04	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock	AQ
27/04	Intellia Announces Proposed Public Offering of Common Stock	AQ
27/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026	AQ
27/04	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing	AQ
27/04	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema	AQ
24/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026	AQ
03/04	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/03	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran, Hereditary Angioedema Patient-Focused Research at AAAAI 2026	AQ